Q1 Earnings Forecast for LXEO Issued By Leerink Partnrs

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Lexeo Therapeutics in a report released on Monday, March 24th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($0.80) per share for the quarter. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.79) EPS and Q4 2025 earnings at ($0.79) EPS.

Several other brokerages have also commented on LXEO. Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday. Leerink Partners decreased their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Monday. Finally, Royal Bank of Canada cut their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $22.80.

Lexeo Therapeutics Stock Up 8.6 %

LXEO stock opened at $4.44 on Wednesday. The stock has a market cap of $146.81 million, a PE ratio of -1.41 and a beta of 3.85. The firm’s 50-day simple moving average is $4.12 and its 200 day simple moving average is $6.67. Lexeo Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.50. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in Lexeo Therapeutics by 107.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock valued at $577,000 after purchasing an additional 33,013 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares in the last quarter. MetLife Investment Management LLC grew its holdings in Lexeo Therapeutics by 121.5% during the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after acquiring an additional 7,803 shares during the period. Vestal Point Capital LP raised its position in Lexeo Therapeutics by 1.2% in the third quarter. Vestal Point Capital LP now owns 850,000 shares of the company’s stock worth $7,684,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Verition Fund Management LLC raised its position in Lexeo Therapeutics by 84.5% in the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock worth $7,027,000 after acquiring an additional 355,928 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.